Apoptosis signal-regulating kinase inhibitor

ABSTRACT

The present invention relates to a compound of formula (I): 
     
       
         
         
             
             
         
       
     
     The compound has apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Patent ApplicationSer. No. 61/591,710, filed Jan. 27, 2012, the entirety of which isincorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to a novel compound for use in thetreatment of ASK1-mediated diseases. The invention also relates tointermediates for its preparation and to pharmaceutical compositionscontaining said novel compound.

BACKGROUND

Apoptosis signal-regulating kinase 1 (ASK1) is a member of themitogen-activated protein kinase kinase kinase (“MAP3K”) family thatactivates the c-Jun N-terminal protein kinase (“JNK”) and p38 MAP kinase(Ichijo, H., Nishida, E., Irie, K., Dijke, P. T., Saitoh, M.,

Moriguchi, T., Matsumoto, K., Miyazono, K., and Gotoh, Y. (1997)Science, 275, 90-94). ASK1 is activated by a variety of stimuliincluding oxidative stress, reactive oxygen species (ROS), LPS, TNF-α,FasL, ER stress, and increased intracellular calcium concentrations(Hattori, K., Naguro, I., Runchel, C., and Ichijo, H. (2009) Cell Comm.Signal. 7:1-10; Takeda, K., Noguchi, T., Naguro, I., and Ichijo, H.(2007) Annu. Rev. Pharmacol. Toxicol. 48: 1-8.27; Nagai, H., Noguchi,T., Takeda, K., and Ichijo, I. (2007) J. Biochem. Mol. Biol. 40:1-6).Phosphorylation of ASK1 protein can lead to apoptosis or other cellularresponses depending on the cell type. ASK1 activation and signaling havebeen reported to play an important role in a broad range of diseasesincluding neurodegenerative, cardiovascular, inflammatory, autoimmune,and metabolic disorders. In addition, ASK1 has been implicated inmediating organ damage following ischemia and reperfusion of the heart,brain, and kidney (Watanabe et al. (2005) BBRC 333, 562-567; Zhang etal., (2003) Life Sci 74-37-43; Terada et al. (2007) BBRC 364: 1043-49).

ROS are reported be associated with increases of inflammatory cytokineproduction, fibrosis, apoptosis, and necrosis in the kidney. (Singh DK,Winocour P, Farrington K. Oxidative stress in early diabeticnephropathy: fueling the fire. Nat Rev Endocrinol 2011 Mar;7(3):176-184;Brownlee M. Biochemistry and molecular cell biology of diabeticcomplications. Nature 2001 Dec 13; 414(6865):813-820; Mimura I, NangakuM. The suffocating kidney: tubulointerstitial hypoxia in end-stage renaldisease. Nat Rev Nephrol 2010 Nov; 6(11):667-678).

Moreover, oxidative stress facilitates the formation of advancedglycation end-products (AGEs) that cause further renal injury andproduction of ROS. (Hung K Y, et al. N-acetylcysteine-mediatedantioxidation prevents hyperglycemia-induced apoptosis and collagensynthesis in rat mesangial cells. Am J Nephrol 2009;29(3):192-202).

Tubulointerstitial fibrosis in the kidney is a strong predictor ofprogression to renal failure in patients with chronic kidney diseases(Schainuck L I, et al. Structural-functional correlations in renaldisease. Part II: The correlations. Hum Pathol 1970; 1: 631-641.).Unilateral ureteral obstruction (UUO) in rats is a widely used model oftubulointerstitial fibrosis. UUO causes tubulointerstital inflammation,increased expression of transforming growth factor beta (TGF-β), andaccumulation of myofibroblasts, which secrete matrix proteins such ascollagen and fibronectin. The UUO model can be used to test for a drug'spotential to treat chronic kidney disease by inhibiting renal fibrosis(Chevalier et al., Ureteral obstruction as a model of renal interstitialfibrosis and obstructive nephropathy, Kidney International (2009) 75,1145-1152.

Thus, therapeutic agents that function as inhibitors of ASK1 signalinghave the potential to remedy or improve the lives of patients in need oftreatment for diseases or conditions such as neurodegenerative,cardiovascular, inflammatory, autoimmune, and metabolic disorders. Inparticular, ASK1 inhibitors have the potential to treat cardio-renaldiseases, including kidney disease, diabetic kidney disease, chronickidney disease, fibrotic diseases (including lung and kidney fibrosis),respiratory diseases (including chronic obstructive pulmonary disease(COPD) and acute lung injury), acute and chronic liver diseases.

U.S. Publication No. 2007/0276050 describes methods for identifying ASK1inhibitors useful for preventing and/or treating cardiovascular diseaseand methods for preventing and/or treating cardiovascular disease in ananimal.

WO2009027283 discloses triazolopyridine compounds, methods forpreparation thereof and methods for treating autoimmune disorders,inflammatory diseases, cardiovascular diseases and neurodegenerativediseases.

U.S. Patent Publication No. 2001/00095410A1, published Jan. 13,2011,discloses compounds useful as ASK-1 inhibitors. U.S. Patent Publication2001/00095410A1 relates to compounds of Formula (I):

wherein:

R¹ is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, orheterocyclyl, all of which are optionally substituted with 1, 2, or 3substituents selected from halo, oxo, alkyl, cycloalkyl, heterocyclyl,aryl, aryloxy, —NO₂, R⁶, —C(O)—R⁶, —OC(O)—R⁶ —C(O)—O—R⁶,—C(O)—N(R⁶)(R⁷), —OC(O)—N(R⁶)(R⁷), —S—R⁶, —S(═O)—R⁶, —S(═O)₂R⁶,—S(═O)₂—N(R⁶)(R⁷), —S(═O)₂—O—R⁶, —N(R⁶)(R⁷), —N(R⁶)—C(O)—R⁷,—N(R⁶)—C(O)—O—R⁷, —N(R⁶)—C(O)—N (R⁶)(R⁷), —N(R⁶)—S(═O)₂—R⁶, —CN, and—O—R⁶,

wherein alkyl, cycloalkyl, heterocyclyl, phenyl, and phenoxy areoptionally substituted by 1, 2, or 3 substituents selected from alkyl,cycloalkyl, alkoxy, hydroxyl, and halo; wherein R⁶ and R⁷ areindependently selected from the group consisting of hydrogen, C₁-C₁₅alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, all of which areoptionally substituted with 1-3 substituents selected from halo, alkyl,mono- or dialkylamino, alkyl or aryl or heteroaryl amide, —CN, loweralkoxy, —CF₃, aryl, and heteroaryl; or R⁶ and R⁷ when taken togetherwith the nitrogen to which they are attached form a heterocycle;

R² is hydrogen, halo, cyano, alkoxy, or alkyl optionally substituted byhalo;

R³ is aryl, heteroaryl, or heterocyclyl, all of which are optionallysubstituted with one or more substituents selected from alkyl, alkoxy,cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl,heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, oxo, —NO₂,haloalkyl, haloalkoxy, —CN, —O—R⁶, —O—C(O)—R⁶, —O—C(O)—N(R⁶)(R⁷), —S—R⁶,—N (R⁶)(R⁷), —S(═O)—R⁶, —S(═O)₂R⁶, —S(═O)₂—N(R⁶)(R⁷), —S(═O)₂—O—R⁶,—N(R⁶)—C(O)—R⁷, —N(R⁶)—C(O)—O—R⁷, —N(R⁶)—C(O)—N(R⁶)(R⁷), —C(O)—R⁶,—C(O)—O—R⁶, —C(O)—N (R⁶)(R⁷), and —N(R⁶)—S(═O)₂—R⁷, wherein the alkyl,alkoxy, cycloalkyl, aryl, heteroaryl or heterocyclyl is furtheroptionally substituted with one or more substituents selected from halo,oxo, —NO₂, alkyl, haloalkyl, haloalkoxy, —N(R⁶)(R⁷), —C(O)—R⁶, —C(O)—O—R⁶, —C(O)—N(R⁶)(R⁷), —CN, —O—R⁶, cycloalkyl, aryl, heteroaryl andheterocyclyl; with the proviso that the heteroaryl or heterocyclylmoiety includes at least one ring nitrogen atom;

X¹, X², X³, X⁴, X⁵, X⁶, X⁷ and X⁸ are independently C(R⁴) or N, in whicheach R⁴ is independently hydrogen, alkyl, alkoxy, cycloalkyl, aryl,heteroaryl, heterocyclyl, halo, —NO₂, haloalkyl, haloalkoxy, —CN, —O—R⁶,—S—R⁶, —N(R⁶)(R⁷), —S(═O)—R⁶, —S(═O)₂R⁶, —S(═O)₂—N(R⁶)(R⁷),—S(═O)₂—O—R⁶, —N(R⁶)—C(O)—R⁷, —N(R⁶)—C(O)—O—R⁷, —N(R⁶)—C(O)—N (R⁶)(R⁷),—C(O)—R⁶, —C(O)—O—R⁶, —C(O)—N(R⁶)(R⁷), or —N(R⁶)—S(═O)₂—R⁷, wherein thealkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl is furtheroptionally substituted with one or more substituents selected from halo,oxo, —NO₂, —CF₃, —O—CF₃, —N(R⁶)(R⁷), —C(O)—R⁶, —C(O)—O—R⁷,—C(O)—N(R⁶)(R⁷), —CN, —O—R⁶; or

X⁵ and X⁶ or X⁶ and X⁷ are joined to provide optionally substitutedfused aryl or optionally substituted fused heteroaryl; and

with the proviso that at least one of X², X³, and X⁴ is C(R⁴);at least two of X⁵, X⁶, X⁷, and X⁸ are C(R⁴); andat least one of X², X³, X⁴, X⁵, X⁶, X⁷ and X⁸ is N.

The above disclosures notwithstanding, there is a need for compoundsthat are potent and exhibit improved pharmacokinetic and/orpharmacodynamic profiles for the treatment of diseases related to ASK1activation.

Surprisingly, applicants have discovered a novel compound within thescope of U.S. patent publication US2011/0009410A exhibiting goodpotency, improved pharmacokinetic and/or pharmacodynamic profiles, onaggregate, compared to compounds disclosed therein.

SUMMARY OF THE INVENTION

The present invention relates to a compound of the formula:

or a pharmaceutically acceptable salt thereof.

In one embodiment, the invention relates to the use of a compound offormula (I) in the treatment of a disease in a patient in need oftreatment with an ASK1 inhibitor.

In another embodiment, the invention relates to a pharmaceuticalcomposition comprising a compound of formula (I) or a pharmaceuticallyacceptable salt thereof, and one or more pharmaceutically acceptablecarriers.

In another embodiment, the invention is a method of treating diabeticnephropathy, or complications of diabetes, comprising administering atherapeutically effective amount of a compound of formula (I) or apharmaceutically acceptable salt thereof, to a patient in need thereof.

In another embodiment, the invention relates to a method of treatingkidney disease, or diabetic kidney disease comprising administering atherapeutically effective amount of a compound of formula (I) or apharmaceutically acceptable salt thereof, to a patient in need thereof.

In another embodiment, the invention relates to a method of treatingkidney fibrosis, lung fibrosis, or idiopathic pulmonary fibrosis (IPF)comprising administering a therapeutically effective amount of acompound of formula (I) or a pharmaceutically acceptable salt thereof,to a patient in need thereof.

In another embodiment, the invention relates to a method of treatingdiabetic kidney disease, diabetic nephropathy, kidney fibrosis, liverfibrosis, or lung fibrosis comprising administering a therapeuticallyeffective amount of a compound or salt of forumia (I), to a patient inneed thereof.

In another embodiment, the invention relates to intermediates useful forthe synthesis of the compound of formula (I).

In another embodiment, the invention relates to the use of a compound offormula (I) or a pharmaceutically acceptable salt thereof for thetreatment of chronic kidney disease.

In another embodiment, the invention relates to the use of a compound offormula (I) or a pharmaceutically acceptable salt thereof for thetreatment of diabetic kidney disease.

In another embodiment, the invention relates to the use of a compound offormula (I) or a pharmaceutically acceptable salt thereof, in themanufacture of a medicament for the treatment of chronic kidney disease.

In yet another embodiment, the invention relates to the compound offormula (I) for use in therapy.

DETAILED DESCRIPTION OF THE INVENTION FIGURES

FIG. 1 is a bar graph showing the levels of Collagen IV in the kidneycortex of rats subjected to seven days of unilateral ureteralobstruction and treated with either vehicle, or compound of formula (I)at 1, 3, 10, or 30 mg/kg b.i.d. per day.

FIG. 2 shows representative images of kidney cortex sections stainedwith alpha-smooth muscle actin (a marker of activated myofibroblasts)from rats subjected to seven days of unilateral ureteral obstruction andtreated with either vehicle, or compound of formula (I) at 1, 3, 10, or30 mg/kg b.i.d. per day.

DEFINITIONS AND GENERAL PARAMETERS

As used herein, the following words and phrases are intended to have themeanings set forth below, except to the extent that the context in whichthey are used indicates otherwise. Where no indication or definition isgiven, the ordinary meaning of the word or phrase as found in a relevantdictionary or in common usage known to one of skill in the art isimplied.

The term “chronic kidney disease” as used herein refers to progressiveloss of kidney function over time typically months or even years.Chronic kidney disease (CKD) is diagnosed by a competent care giverusing appropriate information, tests or markers known to one of skill inthe art. Chronic kidney disease includes by implication kidney disease.

The term “diabetic kidney disease” as used herein refers to kidneydisease caused by diabetes, exacerbated by diabetes, or co-presentingwith diabetes. It is a form of chronic kidney disease occurring inapproximately 30% of patients with diabetes. It is defined as diabeteswith the presence of albuminuria and/or impaired renal function (i.e.decreased glomerular filtration rate (See. de B, I, et al. Temporaltrends in the prevalence of diabetic kidney disease in the UnitedStates. JAMA 2011 Jun 22; 305(24):2532-2539).

The term “pharmaceutically acceptable salt” refers to salts ofpharmaceutical compounds e.g. compound of formula (I) that retain thebiological effectiveness and properties of the underlying compound, andwhich are not biologically or otherwise undesirable. There are acidaddition salts and base addition salts. Pharmaceutically acceptable acidaddition salts may be prepared from inorganic and organic acids.

Acids and bases useful for reaction with an underlying compound to formpharmaceutically acceptable salts (acid addition or base addition saltsrespectively) are known to one of skill in the art. Similarly, methodsof preparing pharmaceutically acceptable salts from an underlyingcompound (upon disclosure) are known to one of skill in the art and aredisclosed in for example, Berge, at al. Journal of PharmaceuticalScience, January 1977 vol. 66, No.1, and other sources. Salts derivedfrom inorganic acids include but are not limited to hydrochloric acid,hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and thelike. Salts derived from organic acids include but are not limited tomaleic acid, fumaric acid, tartaric acid, p-toluene-sulfonic acid, andthe like. Bases useful for forming base addition salts are known to oneof skill in the art. An example of a pharmaceutically acceptable salt ofthe compound of formula (I) is the hydrochloride salt of the compound offormula (I).

As used herein, “pharmaceutically acceptable carrier” includesexcipients or agents such as solvents, diluents, dispersion media,coatings, antibacterial and antifungal agents, isotonic and absorptiondelaying agents and the like that are not deleterious to the compound ofthe invention or use thereof. The use of such carriers and agents toprepare compositions of pharmaceutically active substances is well knownin the art (see, e.g., Remington's Pharmaceutical Sciences, MacePublishing Co., Philadelphia, Pa. 17th Ed. (1985); and ModernPharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G. S. Banker & C. T. Rhodes,Eds.)

The term “cardio-renal diseases” as used herein refers to diseases,related to the function of the kidney, that are caused or exacerbated bycardiovascular problems such as, for example, high blood pressure orhypertension. It is believed that hypertension is a major contributor tokidney disease.

The term “respiratory diseases” as used herein refers to diseasesincluding chronic obstructive pulmonary disease (COPD) and idiopathicpulmonary fibrosis (IPF).

The term “therapeutically effective amount” refers to an amount of thecompound of formula (I) that is sufficient to effect treatment asdefined below, when administered to a patient (particularly a human) inneed of such treatment in one or more doses. The therapeuticallyeffective amount will vary, depending upon the patient, the diseasebeing treated, the weight and/or age of the patient, the severity of thedisease, or the manner of administration as determined by a qualifiedprescriber or care giver.

The term “treatment” or “treating” means administering a compound orpharmaceutically acceptable salt of formula (I) for the purpose of:

-   -   (i) delaying the onset of a disease, that is, causing the        clinical symptoms of the disease not to develop or delaying the        development thereof;    -   (ii) inhibiting the disease, that is, arresting the development        of clinical symptoms; and/or    -   (iii) relieving the disease, that is, causing the regression of        clinical symptoms or the severity thereof.

In a preferred embodiment, the invention relates to the use of thecompound of formula (I) in treating chronic kidney disease comprisingadministering a therapeutically effective amount to a patient in needthereof.

In another preferred embodiment the invention relates to the use of thecompound of formula (I) in treating diabetic kidney disease comprisingadministering a therapeutically effective amount to a patient in needthereof.

In another preferred embodiment the invention relates to the use of thecompound of formula (I) in treating lung or kidney fibrosis comprisingadministering a therapeutically effective amount to a patient in needthereof.

The half maximal inhibitory concentration (IC₅₀) of a therapeutic agentis the concentration of a therapeutic agent necessary to produce 50% ofthe maximum inhibition against a target enzyme. It is a desirable goalto discover a therapeutic agent, for example a compound that inhibitsapoptosis signal-regulating kinase (ASK1) with a low IC₅₀. In thismanner, undesirable side effects are minimized by the ability to use alower dose of the therapeutic agent to inhibit the ASK1 enzyme.

Similarly, it is a desirable goal to discover a therapeutic agent thathas a low dissociation constant (K_(d)). K_(d) is used to describe theaffinity between a ligand (such as a therapeutic agent) and thecorresponding kinase or receptor; i.e. a measure of how tightly atherapeutic agent binds to a particular kinase, for example theapoptosis signal-regulating kinase ASK1. Thus, a lower K_(d) isgenerally preferred in drug development.

Similarly, it is a desirable goal to discover a compound having a lowEC₅₀. EC₅₀ is the concentration of a drug that achieves 50% maximalefficacy in the cell. The EC₅₀ value translates to the concentration ofa compound in the assay medium necessary to achieve 50% of the maximumefficacy. Thus, a lower EC₅₀ is generally preferred for drugdevelopment. A useful unit of measure associated with EC₅₀ is theprotein binding adjusted EC₅₀ (PB_(adj).EC₅₀ as used herein). This valuemeasures the amount of a drug e.g. compound of formula (I) correlated tothe fraction of the drug that is unbound to protein which provides 50%maximal efficacy. This value measures the efficacy of the drug correctedfor or correlated to the amount of drug that is available at the targetsite of action.

Another desirable property is having a compound with a low cell membraneefflux ratio as determined by CACO cell permeability studies. An effluxratio ((B/A)/(A/B)) less than 3.0 is preferred. A compound with a ratiogreater than 3 is expected to undergo active rapid efflux from the celland may not have sufficient duration in the cell to achieve maximalefficacy.

Another desirable goal is to discover a drug that exhibits minimaloff-target inhibition. That is, a drug that minimally inhibits theCyp450 (cytochrome p450) enzymes. More particularly, a drug that is aweak inhibitor of cyp3A4, the most important of the P450 enzymes, isdesired. A weak inhibitor is a compound that causes at least 1.25-foldbut less than 2-fold increase in the plasma AUC values, or 20-50%decrease in clearance (wikipedia.org/wiki/cyp3A4, visited 11/12/11).Generally, a compound exhibiting a Cyp3A4 IC₅₀ of greater than 10uM isconsidered a weak inhibitor.

A measure useful for comparing cyp3A4 inhibition among drug candidatesis the ratio of Cyp3A4 inhibition and the protein binding adjusted EC₅₀.This value gives an indication of the relative potential for cypinhibition corrected for the protein binding adjusted EC₅₀ which isspecific to each drug. A higher ratio in this measure is preferred asindicative of lower potential for cyp3A4 inhibition.

Unexpectedly and advantageously, applicants have discovered a compound(of formula (I) herein) within the generic scope of U.S. Patentpublication No. 2001/00095410A1 that provides advantages compared tostructurally close compounds (herein designated as compounds A and B)disclosed in U.S. Patent publication No. 2001/00095410A1

Therefore, objects of the present invention include but are not limitedto the provision of a compound of formula (I) or pharmaceuticallyacceptable salt thereof, and methods of using the compound of formula(I) for the treatment of kidney disease, chronic kidney disease,diabetic kidney disease, diabetic nephropathy, kidney fibrosis or lungfibrosis.

Combination Therapy

Patients being treated for cardio-renal diseases such as chronic kidneydisease may benefit from combination drug treatment. For example thecompound of the present invention may be combined with one or more ofangiotensin converting enzyme (ACE) inhibitors such as enalapril,captopril, ramipril, lisinopril, and quinapril; or angiontesin IIreceptor blockers (ARBs) such as losartan, olmesartan, and irbesartan;or antihypertensive agents such as amlodipine, nifedipine, andfelodipine. The benefit of combination may be increased efficacy and/orreduced side effects for a component as the dose of that component maybe adjusted down to reduce its side effects while benefiting from itsefficacy augmented by the efficacy of the compound of formula (I) and/orother active component(s).

Patients presenting with chronic kidney disease treatable with ASKIinhibitors such as compound of formula (I), may also exhibit conditionsthat benefit from co-administration (as directed by a qualifiedcaregiver) of a therapeutic agent or agents that are antibiotic,analgesic, antidepressant and/or anti-anxiety agents in combination withcompound of formula (I). Combination treatments may be administeredsimultaneously or one after the other within intervals as directed by aqualified caregiver or via a fixed dose (all active ingredients arecombined into the a single dosage form e.g. tablet) presentation of twoor more active agents.

Pharmaceutical Compositions and Administration

The compound of the present invention may be administered in the form ofa pharmaceutical composition. The present invention therefore providespharmaceutical compositions that contain, as the active ingredient, thecompound of formula (I), or a pharmaceutically acceptable salt thereof,and one or more pharmaceutically acceptable excipients and/or carriers,including inert solid diluents and fillers, diluents, including sterileaqueous solution and various organic solvents, permeation enhancers,solubilizers and adjuvants. The pharmaceutical compositions may beadministered alone or in combination with other therapeutic agents.Compositions may be prepared for delivery as solid tablets, capsules,caplets, ointments, skin patches, sustained release, fast disintegratingtablets, inhalation preparations, etc. Typical pharmaceuticalcompositions are prepared and/or administered using methods and/orprocesses well known in the pharmaceutical art (see, e.g., Remington'sPharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa. 17th Ed.(1985); and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G. S.Banker & C. T. Rhodes, Eds.).

Formulations for combination treatments comprising the compound offormula (I) may be presented as fixed dose formulations e.g. tablets,elixirs, liquids, ointments, inhalants, gels, etc., using proceduresknown to one of skill in the art.

Pharmaceutical compositions of the compound of formula (I) may beadministered in either single or multiple doses by routes including, forexample, rectal, buccal, intranasal and transdermal routes; byintra-arterial injection, intravenously, intraperitoneally,parenterally, intramuscularly, subcutaneously, orally, topically, as aninhalant, or via an impregnated or coated device such as a stent, forexample, or an artery-inserted cylindrical polymer. Most preferredroutes of administration include oral, parental and intravenousadministration.

The compound of formula (I) may be administered in a pharmaceuticallyeffective amount. For oral administration, each dosage unit preferablycontains from 1 mg to 500 mg of the compound of formula (I). A morepreferred dose is from 1 mg to 250 mg of the compound of formula (I).Particularly preferred is a dose of the compound of formula (I) rangingfrom about 20 mg twice a day to about 50 mg twice a day. It will beunderstood, however, that the amount of the compound actuallyadministered usually will be determined by a physician in light of therelevant circumstances including the condition to be treated, the chosenroute of administration, co-administration compound if applicable, theage, weight, response of the individual patient, the severity of thepatient's symptoms, and the like. Nomenclature The name of the compoundof the present invention as generated using ChemBioDraw

Ultra 11.

is5-(4-cyclopropyl-1H-imidazol-1-yl)—N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamidealso known as5-((4-cyclopropyl-1H-imdazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazole-3-yl)pyridine-2-yl)-4-methylbenzamide.

Synthesis of the Compound of Formula (I)

The compound of the invention may be prepared using methods disclosedherein or modifications thereof which will be apparent given thedisclosure herein. The synthesis of the compound of the invention may beaccomplished as described in the following example. If available,reagents may be purchased commercially, e.g. from Sigma Aldrich or otherchemical suppliers. Alternatively, reagents may be prepared usingreaction schemes and methods known to one of skill in the art.

Synthetic Reaction Parameters

The terms “solvent,” “inert organic solvent” or “inert solvent” refer toa solvent inert under the conditions of the reaction being described inconjunction therewith (including, for example, benzene, toluene,acetonitrile, tetrahydrofuran (THF), dimethylformamide (DMF),chloroform, methylene chloride (or dichloromethane), diethyl ether,petroleum ether (PE), methanol, pyridine, ethyl acetate (EA) and thelike. Unless specified to the contrary, the solvents used in thereactions of the present invention are inert organic solvents, and thereactions are carried out under an inert gas, preferably nitrogen.

One method of preparing compounds of formula (I) is shown in ReactionSchemes 1 and 2 below.

Preparation of Compound A

To a solution of methyl 6-aminopicolinate (432 g, 2.84 mol) in MeOH (5L) was added NH₂NH₂.H₂O (284 g, 5.68 mol, 2.0 eq.). The reaction mixturewas heated under reflux for 3 hr and then cooled to room temperature.The precipitate formed in the mixture was collected by filtration,washed with EA (2 L×2) and then dried in vacuo to give compound A (405g, 94% yield) as white solid.

Preparation of Compound B

A mixture of compound A (405 g, 2.66 mol) indimethylformamide-dimethylacetal (DMF-DMA) (3.54 L) was heated underreflux for 18 hr, cooled to room temperature and then concentrated underreduced pressure. The residue was taken up in EA (700 mL) and heated at50° C. for 20 min. After being cooled to room temperature, the solid wascollected by filtration and dried in vacuo to give compound B (572 g,82% yield) as white solid.

Preparation of C

To a solution of compound B (572 g, 2.18 mol) in a mixture of CH₃CN-AcOH(3.6 L, 4:1) was added propan-2-amine (646 g, 5.0 eq.). The resultingmixture was heated under reflux for 24 hr and then cooled to roomtemperature, and the solvent was removed under reduced pressure. Theresidue was dissolved in water (2.8 L) and 1 N aqueous NaOH was added toa pH of 8.0 H. The precipitate was collected by filtration and thefiltrate was extracted with EA (500 mL×3). The combined organic layerswere dried over anhydrous Na₂SO₄, and then concentrated to a volume of150 mL. To this mixture at 0° C. was slowly added PE (400 mL) and theresulting suspension was filtered. The combined solid wasre-crystallized from EA-PE to give compound C (253 g, 57% yield) asoff-white solid.

¹H-NMR (400 MHz, CDC13): δ 8.24 (s, 1H), 7.52 (m, 2 H), 6.51 (dd, J=1.6,7.2 Hz, 1H), 5.55 (m, 1H), 4.46 (bs, 2 H), 1.45 (d, J=6.8 Hz, 6 H). MS(ESI+) m/z: 204 (M+1)⁺. Compound C is a key intermediate for thesynthesis of the compound of formula (I). Thus, an object of the presentinvention is also the provision of the intermediate compound C,

its salts or protected forms thereof, for the preparation of thecompound of formula (I). An example of a salt of the compound C is theHCl addition salt. An example of a protected form of compound C is thecarbamate compound such as obtained with Cbz-Cl. Protective groups,their preparation and uses are taught in Peter G. M. Wuts and TheodoraW. Greene, Protective Groups in Organic Chemistry, 2^(nd) edition, 1991,Wiley and Sons, Publishers.Preparation of the Compound of formula (I) continued:

Compound 6 is a key intermediate for the synthesis of the compound offormula (I). Thus an object of the present invention is also theprovision of intermediate compound 6,

salts or protected forms thereof, for the preparation of the compound offormula (I). An example of a salt of the compound 6 is the HCl additionsalt. An example of a protected form of the compound 6 is an ester (e.g.methyl, ethyl or benzyl esters) or the carbamate compound such asobtained with Cbz-Cl. Protective groups, their preparations and uses aretaught in Peter G. M. Wuts and Theodora W. Greene, Protective Groups inOrganic Chemistry, 2^(nd) edition, 1991, Wiley and Sons, Publishers.Step 1—Preparation of 5-amino-2-fluoro-4-methylbenzonitrile—Compound (2)

The starting 5-bromo-4-fluoro-2-methylaniline (1) (20 g, 98 mmol) wasdissolved in anhydrous 1-methylpyrrolidinone (100 mL), and copper (I)cyanide (17.6 g, 196 mmol) was added. The reaction was heated to 180° C.for 3 hours, cooled to room temperature, and water (300 mL) andconcentrated ammonium hydroxide (300 mL) added. The mixture was stirredfor 30 minutes and extracted with EA (3×200 mL). The combined extractswere dried over magnesium sulfate, and the solvent was removed underreduced pressure. The oily residue was washed with hexanes (2×100 mL),and the solid dissolved in dichloromethane and loaded onto a silica gelcolumn. Eluting with 0 to 25% EA in hexanes gradient provided5-amino-2-fluoro-4-methylbenzonitrile (10.06g, 67.1 mmol). LC/MS(m/z:151 M⁺¹).

Step 2—Preparation of5-(2-cyclopropyl-2-oxoethylamino)-2-fluoro-4-methylbenzonitrile—Compound(3)

5-Amino-2-fluoro-4-methylbenzonitrile (12 g, 80 mmol) was dissolved inanhydrous N,N-dimethylformamide (160 mL) under nitrogen, and potassiumcarbonate (13.27 g, 96 mmol) and potassium iodide (14.61 g, 88 mmol)were added as solids with stirring. The reaction was stirred for 5minutes at room temperature and then bromomethyl cyclopropylketone(20.24 mL, 180 mmol) was added. The reaction mixture was heated to 60°C. for 3 hours, and then the solvents removed under reduced pressure.The residue was dissolved in EA (400 mL) and washed with 400 mL ofwater. The organic layer was dried over magnesium sulfate, and solventwas removed under reduced pressure. The residue was re-dissolved in aminimum amount of EA, and hexanes were added to bring the solution to3:1 hexanes: EA by volume. The product precipitated out of solution andwas collected by filtration to provide5-(2-cyclopropyl-2-oxoethylamino)-2-fluoro-4-methylbenzonitrile (14.19g, 61.2 mmol). LC/MS (m/z : 233, M⁺¹)

Step 3—Preparation of5-(4-cyclopropyl-2-mercapto-1H-imidazol-1-yl)-2-fluoro-4-methylbenzonitrile—Compound(4)

5-(2-Cyclopropyl-2-oxoethylamino)-2-fluoro-4-methylbenzonitrile (14.19g, 61.2 mmol) was dissolved in glacial acetic acid (300 mL). Potassiumthiocyanate (11.9 g, 122.4 mmol) was added as a solid with stirring. Thereaction mixture was heated to 110° C. for 4 hours at which time thesolvent was removed under reduced pressure. The residue was taken up indichloromethane (200 mL) and washed with 200 mL water. The aqueousextract was extracted with (2×200 mL) additional dichloromethane, theorganic extracts combined and dried over magnesium sulfate. The solventwas removed under reduced pressure and the oily residue was re-dissolvedin EA (50 mL) and 150 mL hexanes was added. A dark layer formed and astir bar was added to the flask. Vigorous stirring caused the product toprecipitate as a peach colored solid. The product was collected byfiltration, to yield5-(4-cyclopropyl-2-mercapto-1H-imidazol-1-yl)-2-fluoro-4-methylbenzonitrile,(14.26 g, 52.23 mmol). Anal. LC/MS (m/z : 274, M⁺¹)

Step 4—Preparation of5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methylbenzonitrile—Compound(5)

In a 500 mL three neck round bottom flask was placed acetic acid (96mL), water (19 mL) and hydrogen peroxide (30%, 7.47 mL, 65.88 mmol). Themixture was heated to 45° C. with stirring under nitrogen whilemonitoring the internal temperature.5-(4—Cyclopropyl-2-mercapto-1H-imidazol-1-yl)-2-fluoro-4-methylbenzonitrile(6.00 g, 21.96 mmol) was then added as a solid in small portions over 30minutes while maintaining an internal temperature below 55° C. Whenaddition of the thioimidazole was complete the reaction was stirred for30 minutes at a temperature of 45° C., and then cooled to roomtemperature, and a solution of 20% wt/wt sodium sulfite in water (6 mL)was slowly added. The mixture was stirred for 30 minutes and solventswere removed under reduced pressure. The residue was suspended in 250 mLof water and 4N aqueous ammonium hydroxide was added to bring the pH to˜10. The mixture was extracted with dichloromethane (3×200 ml), theorganics combined, dried over magnesium sulfate, and the solvent wasremoved under reduced pressure. The residue was dissolved in 20 mL EA,and 80 mL of hexanes were added with stirring. The solvents weredecanted off and an oily residue was left behind. This process wasrepeated and the product,5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methylbenzonitrile wasobtained as a viscous oil (5.14 g, 21.33 mmol) Anal. LC/MS (m/z: 242,M⁺¹)

Step 5—Preparation of5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methylbenzoic acidhydrochloride (6)

5-(4-Cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methylbenzonitrile (11.21g, 46.50 mmol) was placed in a round bottom flask fitted with a refluxcondenser, and suspended in 38% hydrochloric acid (200 mL). The mixturewas heated to 100° C. for 4.5 hours, and then cooled to roomtemperature. Solvent was removed under reduced pressure to give a pinksolid, to which was added 100 ml of EA. The solid product was collectedby filtration and washed with 3×100 mL EA. To the solid product wasadded 100 mL 10% methanol in dichloromethane, the mixture stirred, andthe filtrate collected. This was repeated with 2 more 100 ml portions of10% methanol in dichloromethane. The filtrates were combined and solventwas removed under reduced pressure, to provide crude5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methylbenzoic acidhydrochloride. No further purification was carried out (11.13 g, 37.54mmol). Anal. LC/MS (m/z: 261, M⁺¹)

Step 6—Preparation of5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro—N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide—formula (I)

5-(4-Cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methylbenzoic acidhydrochloride (1.5 g, 5.07 mmol) was suspended in anhydrous1,2-dichloromethane (25 mL) at room temperature. Oxalyl chloride (0.575ml, 6.59 mmol) was added with stirring under nitrogen, followed byN,N-dimethylformamide (0.044 ml, 0.507 mmol). The mixture was stirredfor 4 hr at room temperature, and then the solvent was removed underreduced pressure. The residue was dissolved in 25 mL anhydrousdichloromethane. 6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-amine(1.13 g, 5.58 mmol) (compound C) and 4-dimethylaminopyridine (0.62 g,5.07 mmol) were rapidly added with stirring under nitrogen. The reactionwas stirred for 2 hours at room temperature and aqueous saturated NaHCO₃(15 mL) was added. The mixture was stirred for 10 minutes, and thelayers were separated, and the aqueous layer was washed 1×20 mLdichloromethane. The combined organics were dried (MgSO₄), filtered andconcentrated. The residue was dissolved in a minimum amount of CH₃CN andwater was slowly added until solids precipitated from the mixture. Thesolid was collected by filtration and dried to give5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl) pyridin-2-yl)-4-methylbenzamide in ˜96% purity (1.28 g, 2.88 mmol).Anal. LC/MS (m/z: 446, M⁺¹). The material was further purified byRP-HPLC (reverse phase HPLC) to obtain an analytically pure sample asthe HCl salt.

C₂₄H₂₄FN₇O—HCl. 446.2 (M+1). ¹H-NMR (DMSO): δ 11.12 (s, 1H), 9.41 (s,1H), 9.32 (s, 1H), 8.20 (d, J=8.4 Hz, 1H), 8.07 (t, J=8.4 Hz, 1H), 7.95(d, J=6.4 Hz, 1H), 7.92 (d, J=7.6 Hz, 1H), 7.79 (s, 1H), 7.59 (d, J=10.4Hz, 1H), 5.72 (sept, J=6.8 Hz, 1H), 2.29 (s, 3H), 2.00-2.05 (m, 1H),1.44 (d, J=6.8 Hz, 6H), 1.01-1.06 (m, 2H), 0.85-0.89 (m, 2H).

Biological Assays ASK1 (Apoptosis Signal-Regulating Kinase 1) TR-FRETKinase Assay (Biochemical IC₅₀)

The ability of compounds to inhibit ASK1 kinase activity was determinedusing a time resolved fluorescence resonance energy transfer [TR-FRET]assay utilizing biotinylated myelin basic protein [biotin-MBP] as theprotein substrate. A Beckman Biomek FX liquid handling robot wasutilized to spot 2 μL/well of compounds in 2.44% aqueous DMSO into lowvolume 384-well polypropylene plates [Nunc, #267460] to give a finalconcentration of between 100 μM and 0.5nM compound in the kinase assay.A Deerac Fluidics Equator was used to dispense 3 μL/well of 0.667ng/μL[Upstate Biotechnologies, #14-606, or the equivalent protein preparedin-house] and 0.1665 ng/mL biotin-MBP [Upstate Biotechnologies, #13-111]in buffer (85 mM MOPS, pH 7.0, 8.5 mM Mg-acetate, 5% glycerol, 0.085%NP-40, 1.7mM DTT and 1.7 mg/mL BSA) into the plates containing thespotted compounds.

The enzyme was allowed to pre-incubate with compound for 20 minutesprior to initiating the kinase reaction with the addition of 5 μL/well300 μM ATP in buffer (50 mM MOPS, pH 7.0, 5 mM Mg-acetate, 1 mM DTT, 5%DMSO) using the Deerac Fluidics Equator. The kinase reactions wereallowed to proceed for 20 minutes at ambient temperature and weresubsequently stopped with the addition of 5 μL/well 25 mM EDTA using theDeerac Fluidics Equator. The Biomek FX was then used to transfer 1μL/well of each completed kinase reaction to the wells of anOptiPlate-1536 white polystyrene plate [PerkinElmer, #6004299] thatcontained 5 μL/well detection reagents (1.11 nM Eu-W1024 labeledanti-phosphothreonine antibody [PerkinElmer, #AD0094] and 55.56 nMstreptavidin allophycocyanin [PerkinElmer, #CR130-100] in 1× LANCEdetection buffer [PerkinElmer, #CR97-100]). The TR-FRET signal was thenread on a Perkin Elmer Envision plate reader after incubating the platesat ambient temperature for 2 hours.

The 100% inhibition positive control wells were generated by switchingthe order of addition of the EDTA and ATP solutions described above.These wells and 0% inhibition wells containing spots of 2.44% DMSO atthe beginning of the assay were used in calculating the % inhibition forthe test compounds.

Result

The compound of formula (I) inhibited ASK1 with an IC₅₀ of 3.0 nM. Thisdata suggests that the compound of formula (I) is a potent inhibitor ofASK1 in the presence of the competitive ligand ATP.

In an updated version of the assay above, the inhibitory activity ofcompound of the invention against ASK1 was examined using a TR-FRET ASK1assay which determined the amount of phosphate transferred to a peptidesubstrate from ATP.

Materials and Methods Reagents

Dephosphorylated recombinant human ASK1 kinase was from Gilead Sciences.Small molecule kinase inhibitor staurosporine (Catalogue #S6942) anddithiothreitol (DTT, catalogue #43815-5G) were obtained from SigmaChemicals (St. Louis, Mo.). ATP (catalogue #7724) was from Affymetrix(Santa Clara, Calif.) and the compound of formula (I) was from GileadSciences. HTRF KinEASE™—STK S3 kit was obtained from Cisbio (Bedford,Mass). All other reagents were of the highest grade commerciallyavailable.

Assays

The assay measures the phosphorylation level of a biotinylated peptidesubstrate by the ASK1 kinase using HTRF detection (6.1). This is acompetitive, time-resolved fluorescence resonance energy transfer(TR-FRET) immunoassay, based on HTRF® KinEASE™—STK manual from Cisbio(6.1). Test compound, 1 μM STK3 peptide substrate, 4 nM of ASK1 kinaseare incubated with 10 mM MOP buffer, pH. 7.0 containing 10 mMMg-acetate, 0.025% NP-40, 1 mM DTT, 0.05% BSA and 1.5% glycerol for 30minutes then 100 □M ATP is added to start the kinase reaction andincubated for 3 hr. Peptide antibody labeled with 1× Eu³⁺ Cryptatebuffer containing 10 mM EDTA and 125 nM Streptavidin XL665 are added tostop the reaction and phosphorylated peptide substrate is detected usingEnvision 2103 Multilabeled reader from PerkinElmer. The fluorescence ismeasured at 615 nm (Cryptate) and 665 nm (XL665) and a ratio of 665nm/615 nm is calculated for each well. The resulting TR-FRET level (aratio of 665 nm/615 nm) is proportional to the phosphorylation level.Under these assay conditions, the degree of phosphorylation of peptidesubstrate was linear with time and concentration for the enzyme. Theassay system yielded consistent results with regard to K_(m) andspecific activities for the enzyme. For inhibition experiments (IC₅₀values), activities were performed with constant concentrations of ATP,peptide and several fixed concentrations of inhibitors. Staurosporine,the nonselective kinase inhibitor, was used as the positive control. Allenzyme activity data are reported as an average of quadruplicatedetermination.

Data Analysis

The IC₅₀ values were calculated following equation:

y=Range/{1+(x/IC₅₀)^(s)}+Background

Where x and y represent the concentration of inhibitors and enzymeactivity, respectively. Enzyme activity is expressed as the amount ofPhosphate incorporated into substrate peptide from ATP. Range is themaximum y range (no inhibitor, DMSO control) and s is a slope factor(6.2).

Results

The compound of formula (I) exhibited an IC50 of 3.2 nM under this testcondition. The data demonstrates that the compound of formula (I) is apotent inhibitor of the ASK-1 1 receptor.

ASK1 (Apoptosis Signal-Regulating Kinase 1) 293 Cell-Based Assay(Cellular EC₅₀)

The cellular potency of compounds was assayed in cells stably expressingan AP-1:luciferase reporter construct (293/AP1-Luc cells - PanomicsInc., 6519 Dumbarton Circle, Fremont, Calif.). Cells were infected withan adenovirus expressing kinase active ASK1 (631-1381 of rat ASK1 cDNA),which will activate the AP-1 transcription factor and increase theexpression of luciferase. Inhibitors of ASK1 will decrease the enzymeactivity of ASK1 and therefore decrease the activity of AP-1transcription factor and the expression of luciferase.

1. Materials Required for This Protocol

Media and Reagents Source Company Catalog No. AP-1 Reporter 293 StableCell Line Panomics Unknown DMEM (w/high glucose, w/o L- MediaTech15-018-CM glutamine, w/pyruvate, w/HEPES DMEM (w/high glucose, w/o L-Invitrogen 31053-028 glutamine, w/o pyruvate, w/o HEPES, w/o phenol redHEPES, 1M Invitrogen 15630-080 Sodium Pyruvate, 100 mM Invitrogen11360-070 Fetal Bovine Serum, “FBS” Hyclone SH30088.03 Pen-Strep-Glut.,“PSG” Invitrogen 10378-016 HygromycinB Calbiochem 400052 Dulbecco's PBS(sterile) MediaTech 21-030-CM Trypsin-EDTA (0.25%) Invitrogen 25200-056Steady-Glo Luciferase Assay Promega E2550 System Labware Source CatalogNo. Flasks (poly-D-Lysine coated, 150 BD Biosciences 356538 cm², ventedcap) Plates (poly-D-Lysine coated, 384- Greiner (through 781944 well,white/clear, sterile TCT) VWR Scientific) (82051-354) White Backing TapePerkinElmer 6005199 Cell Strainers (40 um nylon, blue VWR Scientific21008-949 ring, fits 50 mL conical vials)

2. Reference Materials

Panomics 293/AP1-Luc stable cell-line product insert.Promega Steady-Glo Luciferase Assay System product insert.

3. Media Required Complete Growth Medium, “CGM” DMEM (MediaTech) 10% FBS1% PSG

100 ug/mL HygromycinB

Assay Medium, “AM” DMEM (Invitrogen) 25 mM HEPES 1 mM Sodium Pyruvate 1%PSG 4. Methods Maintenance:

293/AP1-Luc Maintain 293/Acells per vendor's instructions; harvest cellsat ˜80% confluence in T150 flasks as follows:

Aspirate media, wash gently with ˜12 mL sterile D-PBS, aspirate.Add 5 mL Trypsin-EDTA, tilt gently to coat flask, and incubate ˜5 min at37° C.Do not tap flask; add 5 mL CGM, wash flask 4X with cell suspension,transfer to 50 mL conical vial, centrifuge 5 min at 1200 rpm.Aspirate media from cell pellet, add 20 to 30 mL CGM, resuspend pelletby pipeting 6×, pass through cell strainer to disperse clumps (ifnecessary), and count cells with hemocytometer.

Assay Day 1:

Harvest cells as above, except resuspend cell pellet.

Count cells and dilute to 1.5×10⁵ cells per mL; add adenovirus such thatthere are 5 infectious forming units per cell.

Prime (20 to 30 mL) and plate cells in Greiner poly-D-Lysine coated384-well plates at 1.2×10⁴ cells per well using BioTek uFill (80 uL perwell).Immediately dose plates with 0.4 uL of compound dose series (in 100%DMSO) incubate 24 hours in humidified incubator (37° C., 5% CO₂).

Assay Day 2:

Process plates (per manufacturer's instructions) as follows:

Set plates in laminar flow hood & uncover for 30 minutes at roomtemperature to cool.Remove 60 uL of AM from assay wellsAdd 20 uL per well Steady-Glo Firefly substrate, let sit for 10-20minutes at room temperatureCover bottom of assay plates with white backing tape.Acquire data on a fluorescence plate readerThe 100% inhibition positive control wells were generated by infectingcells with an adenovirus expressing catalytically inactive ASK1 mutantwith lysine to argine mutation at residue 709.

Result

The compound of formula (I) exhibits an EC₅₀ of 2.0 nM.

Determination of Kd Kinase Assays

Kinase-tagged T7 phage strains were prepared in an E. coli host derivedfrom the BL21 strain. E. coli were grown to log-phase and infected withT7 phage and incubated with shaking at 32° C. until lysis. The lysateswere centrifuged and filtered to remove cell debris. The remainingkinases were produced in HEK-293 cells and subsequently tagged with DNAfor qPCR detection. Streptavidin-coated magnetic beads were treated withbiotinylated small molecule ligands for 30 minutes at room temperatureto generate affinity resins for kinase assays.

The liganded beads were blocked with excess biotin and washed withblocking buffer (SeaBlock (Pierce), 1% (bovine serum albumin), 0.05%Tween 20, 1 mM DTT(dithiothreitol)) to remove unbound ligand and toreduce non-specific binding. Binding reactions were assembled bycombining kinases, liganded affinity beads, and test compounds in 1×binding buffer (20% SeaBlock, 0.17×PBS, 0.05% Tween 20, 6 mM DTT). Allreactions were performed in polystyrene 96-well plates in a final volumeof 0.135 mL. The assay plates were incubated at room temperature withshaking for 1 hour and the affinity beads were washed with wash buffer(1×PBS, 0.05% Tween 20). The beads were then re-suspended in elutionbuffer (1×PBS, 0.05% Tween 20, 0.5 μM non-biotinylated affinity ligand)and incubated at room temperature with shaking for 30 minutes. Thekinase concentration in the eluates was measured by qPCR.

Binding constants (Kds) were calculated with a standard dose-responsecurve using the Hill equation.

Result

The compound of formula (I) exhibited a K_(d) of 0.24 nM. This datasuggests that the compound of formula (I) binds potently to ASK1receptor in the absence of ATP.

Determination of Percent of Compound Bound to Plasma ExperimentalDesign:

1 mL Teflon dialysis cells from Harvard Apparatus (Holliston, Mass.,USA) were used in these experiments. Prior to the study, dialysismembrane was soaked for approximately one hour in 0.133 M phosphatebuffer, pH 7.4. A nominal concentration of 2 μM of compound was spikedinto 1 mL of plasma or 1 mL of cell culture media. The total volume ofliquid on each side of the cell was 1 mL. After 3 hours equilibration ina 37° C. water bath, samples from each side of the cell were aliquotedinto the appropriate vials containing either 1 mL of human plasma (cellculture media), or buffer. Sample vials were weighed and recorded. A 100μL aliquot was removed and added to 400 μL quenching solution (50%methanol, 25% acetonitrile, 25% water and internal standard). Sampleswere vortexed and centrifuged for 15 minutes at 12000 G. 200 pL of thesupernatant was removed and placed into a new 96 well plate. Anadditional 200 μL of 1:1 ACN:water was added. The plate was thenvortexed and subjected to LC-MS analysis. The percent unbound for ananalyte in plasma was calculated using the following equations

% Unbound=100(C _(f) /C _(t))

where C_(f) and C_(t) are the post-dialysis buffer and plasmaconcentrations, respectively.

Results

The percent unbound measured in human plasma for the compound of formula(I) is 11.94%

Determination of CACO-2 Efflux Ratio Experimental:

Caco-2 cells were maintained in Dulbecco's Modification of Eagle'sMedium (DMEM) with sodium pyruvate, Glutmax supplemented with 1%Pen/Strep, 1% NEAA and 10% fetal bovine serum in an incubator set at 37°C., 90% humidity and 5% CO₂. Caco-2 cells between passage 62 and 72 wereseeded at 2100 cells/well and were grown to confluence over at least21-days on 24 well PET (polyethylene-terephthalate) plates (BDBiosciences). The receiver well contained HBSS buffer (10 mM HEPES, 15mM Glucose with pH adjusted to pH 6.5) supplemented with 1% BSA pHadjusted to pH 7.4. After an initial equilibration with transportbuffer, TEER values were read to test membrane integrity. Bufferscontaining test compounds were added and 100 μl of solution was taken at1 and 2 hrs from the receiver compartment. Removed buffer was replacedwith fresh buffer and a correction is applied to all calculations forthe removed material. The experiment was carried out in replicate. Allsamples were immediately collected into 400 μl 100% acetonitrile acid toprecipitate protein and stabilize test compounds. Cells were dosed onthe apical or basolateral side to determine forward (A to B) and reverse(B to A) permeability. Permeability through a cell free trans-well isalso determined as a measure of cellular permeability through themembrane and non-specific binding. To test for non-specific binding andcompound instability percent recovery is determined. Samples wereanalyzed by LC/MS/MS.

The apparent permeability, P_(app), and % recovery were calculated asfollows:

P _(app)=(dR/dt)×V _(r)/(A×D ₀)

% Recovery=100×((V _(r) ×R ₁₂₀)+(V _(d) ×D ₁₂₀))/(V _(d) ×D ₀)

where,dR/dt is the slope of the cumulative concentration in the receivercompartment versus time inμM/s based on receiver concentrations measured at 60 and 120 minutes.V_(r) and V_(d) is the volume in the receiver and donor compartment incm³, respectively.A is the area of the cell monolayer (0.33 cm²).D₀ and D₁₂₀ is the measured donor concentration at the beginning and endof the experiment, respectively.R₁₂₀ is the receiver concentration at the end of the experiment (120minutes).

Absorption and Efflux Classification:

P_(app) (A to B) ≥ 1.0 × 10⁻⁶ cm/s High 1.0 × 10⁻⁶ cm/s > P_(app) (A toB) ≥ Medium 0.5 × 10⁻⁶ cm/s P_(app) (A to B) < 0.5 × 10⁻⁶ cm/s LowP_(app) (B to A)/P_(app) (A to B) ≥ 3 Significant Efflux % recovery <20% May affect measured permeability Cell Free P_(app) < 15 May affectmeasured permeability

Result

The compound of formula (I) was observed to have a CACO A→B value of 27;and a CACO B→A value of 35 resulting in a efflux ratio (B→A)/(A→B) of1.3.

Determination of Metabolic Stability in Hepatic Microsomal Fraction:Experimental:

Metabolic stability was assessed using cofactors for both oxidativemetabolism (NADPH) and conjugation (UDP glucuronic acid (UDPGA)).Duplicate aliquots of the compound of formula (I) (3 μL of 0.5 mM DMSOstock) or metabolic stability standards (Buspirone) were added tomicrosome stock diluted with potassium phosphate buffer, pH 7.4, toobtain a protein concentration of 1.0 mg/mL and containing alamethicinas a permeabilizing agent. Metabolic reactions were initiated by theaddition of NADPH regenerating system and UDPGA cofactor. The finalcomposition of each reaction mixture was: 3 μM test compound, 1 mgmicrosomal protein/mL, 5 mM UDPGA, 23.4 μg/mL alamethicin, 1.25 mM NADP,3.3 mM glucose-6-phosphate, 0.4 U/mL glucose-6-phosphate dehydrogenaseand 3.3 mM MgCl₂ in 50 mM potassium phosphate buffer, pH 7.4. At 0, 2,5, 10, 15, 30, 45, and 60 min, 25 μL aliquots of the reaction mixturewere transferred to plates containing 250 μl of IS/Q (quenching solutioncontaining internal standard). After quenching, the plates werecentrifuged at 3000×g for 30 minutes, and 10 μL aliquots of thesupernatant were analyzed using LC/MS to obtain analyte/internalstandard peak area ratios.

Metabolic stability in microsomal fractions were determined by measuringthe rate of disappearance of the compound of formula (I). Data (% ofparent remaining) were plotted on a semi logarithmic scale and fittedusing an exponential fit:

C _(t) =C ₀ ·e ^(−K·t) and T _(1/2)=ln2/K where

C_(t) % of parent remaining at time=tC₀ % of parent remaining at time=0t time (hr)K First order elimination rate constant (hr⁻¹)T½ In vitro half-life (hr)The predicted hepatic clearance was calculated as follows {reference 1}:

CL _(int) =K·V·Y _(P) /P or CL _(int) =K·V·Y _(H) /H

CL _(h)=(CL _(int) ·Q _(h))/(CL _(int) +Q _(h)), where

CL_(h) Predicted hepatic clearance (L/hr/kg body weight)CL_(int) Intrinsic hepatic clearance (L/hr/kg body weight)V Incubation volume (L)Y_(P) Microsome protein yield (mg protein/kg body weight)Y_(H) Hepatocyte yield (millions of cells/kg body weight)P Mass of protein in the incubation (mg)H Number of hepatocytes in the incubation (million)Q_(h) Hepatic blood flow (L/hr/kg body weight)

Predicted hepatic extraction was then calculated by comparison ofpredicted hepatic clearance to hepatic blood flow. A compound wasconsidered stable if the reduction of substrate concentration was <10%over the course of the incubation (corresponding to an extrapolatedhalf-life of >395 min in microsomal fractions and >39.5 hr inhepatocytes).

Values used for calculation of the predicted hepatic clearance are shownin the tables below:

TABLE 1 Values Used for Calculation of the Predicted Hepatic Clearancefrom Microsomal Stability Hepatic Microsomes V P Y Q_(h) Species (L)(mg) (mg/kg) (L/kg) Rat 0.001 1.0 1520 4.2 Cynomolgus Monkey 0.001 1.0684 1.6 Rhesus Monkey 0.001 1.0 1170 2.3 Dog 0.001 1.0 1216 1.8 Human0.001 1.0 977 1.3

Result:

The predicted hepatic clearance in human as determined from in vitroexperiments in microsomal fractions is 0.1 L/h/kg.

Determination of Rat CL and Vss for Test Compounds

Pharmacokinetics of Test Compounds following a 1 mg/kg IV infusion and5.0 mg/kg PO dose in rats

Test Article and Formulation

For IV administration the test compound was formulated in 60:40 PEG400:water with 1 equivalent HCl at 0.5 mg/mL. The formulation was asolution. For PO (oral) administration, the test compound was formulatedin 5/75/10/10 ethanol/PG/solutol/water at 2.5 mg/mL. The formulation wasa solution.

Animals Used

IV and PO dosing groups each consisted of 3 male SD rats. At dosing, theanimals generally weighed between 0.317 and 0.355 kg. The animals werefasted overnight prior to dose administration and up to 4 hr afterdosing.

Dosing

For the IV infusion group, the test compound was administered byintravenous infusion over 30 minutes. The rate of infusion was adjustedaccording to the body weight of each animal to deliver a dose of 1 mg/kgat 2 mL/kg. For the oral dosing group, the test article was administeredby oral gavage at 2 mL/kg for a dose of 5.0 mg/kg.

Sample Collection

Serial venous blood samples (approximately 0.4 mL each) were taken atspecified time points after dosing from each animal. The blood sampleswere collected into Vacutainer™ tubes (Becton-Disckinson Corp, N.J.,USA) containing EDTA as the anti-coagulant and were immediately placedon wet ice pending centrifugation for plasma.

Determination of the Concentrations of the Compound of Formula (I) inPlasma

An LC/MS/MS method was used to measure the concentration of testcompound in plasma.

Calculations

Non-compartmental pharmacokinetic analysis was performed on the plasmaconcentration-time data.

Results

The compound of formula (I) exhibited a CL of 0.09 L/hr/kg; an oralbioavailability of 75%; t₁₁₂ of 5.07 hr and a Vss of 0.55 L/kg in rats.

Cyp Inhibition Assay Objective

To assess the potential of the test compound to inhibit the maincytochrome P450 isoforms, CYP1A, CYP1A2, CYP2B6, CYP2C8, CYP2C9,CYP2C19, CYP2D6 and CYP3A4 (2 substrates).

Cytochrome P450 Inhibition IC₅₀ Determination (8 Isoform, 9 Substrates)Protocol Summary

Test compound (0.1 μM-25 μM) is incubated with human liver microsomesand NADPH in the presence of a cytochrome P450 isoform-specific probesubstrate. For the CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4specific reactions, the metabolites are monitored by mass spectrometry.CYP1A activity is monitored by measuring the formation of a fluorescentmetabolite. A decrease in the formation of the metabolite compared tothe vehicle control is used to calculate an IC50 value (test compoundconcentration which produces 50% inhibition).

Assay Requirements

500 μL of a 10 mM test compound solution in DMSO.

Experimental Procedure CYP1A Inhibition

Six test compound concentrations (0.1, 0.25, 1, 2.5, 10, 25 μM in DMSO;final DMSO concentration=0.3%) are incubated with human liver microsomes(0.25 mg/mL) and NADPH (1 mM) in the presence of the probe substrateethoxyresorufin (0.5 μM) for 5 min at 37° C. The selective CYP1Ainhibitor, alpha-naphthoflavone, is screened alongside the testcompounds as a positive control.

CYP2B6 Inhibition

Six test compound concentrations (0.1, 0.25, 1, 2.5, 10, 25 μM in DMSO;final DMSO concentration=0.3%) are incubated with human liver microsomes(0.1 mg/mL) and NADPH (1 mM) in the presence of the probe substratebupropion (110 μM) for 5 min at 37° C. The selective CYP2B6 inhibitor,ticlopidine, is screened alongside the test compounds as a positivecontrol.

CYP2C8 Inhibition

Six test compound concentrations (0.1, 0.25, 1, 2.5, 10, 25 μM in DMSO;final DMSO concentration=0.3%) are incubated with human liver microsomes(0.25 mg/mL) and NADPH (1 mM) in the presence of the probe substratepaclitaxel (7.5 μM) for 30 min at 37° C. The selective CYP2C8 inhibitor,montelukast, is screened alongside the test compounds as a positivecontrol.

CYP2C9 Inhibition

Six test compound concentrations (0.1, 0.25, 1, 2.5, 10, 25 μM in DMSO;final DMSO concentration=0.25%) are incubated with human livermicrosomes (1 mg/mL) and NADPH (1 mM) in the presence of the probesubstrate tolbutamide (120 μM) for 60 min at 37° C. The selective CYP2C9inhibitor, sulphaphenazole, is screened alongside the test compounds asa positive control.

CYP2C19 Inhibition

Six test compound concentrations (0.1, 0.25, 1, 2.5, 10, 25 μM in DMSO;final DMSO concentration=0.25%) are incubated with human livermicrosomes (0.5 mg/mL) and NADPH (1 mM) in the presence of the probesubstrate mephenytoin (25 μM) for 60 min at 37° C. The selective CYP2C19inhibitor, tranylcypromine, is screened alongside the test compounds asa positive control.

CYP2D6 Inhibition

Six test compound concentrations (0.1, 0.25, 1, 2.5, 10, 25 μM in DMSO;final DMSO concentration=0.25%) are incubated with human livermicrosomes (0.5 mg/mL) and NADPH (1 mM) in the presence of the probesubstrate dextromethorphan (5 μM) for 5 min at 37° C. The selectiveCYP2D6 inhibitor, quinidine, is screened alongside the test compounds asa positive control.

CYP3A4 Inhibition (Midazolam)

Six test compound concentrations (0.1, 0.25, 1, 2.5, 10, 25 μM in DMSO;final DMSO concentration=0.26%) are incubated with human livermicrosomes (0.1 mg/mL) and NADPH (1 mM) in the presence of the probesubstrate midazolam (2.5 μM) for 5 min at 37° C. The selective CYP3A4inhibitor, ketoconazole, is screened alongside the test compounds as apositive control.

CYP3A4 Inhibition (Testosterone)

Six test compound concentrations (0.1, 0.25, 1, 2.5, 10, 25 μM in DMSO;final DMSO concentration=0.275%) are incubated with human livermicrosomes (0.5 mg/mL) and NADPH (1 mM) in the presence of the probesubstrate testosterone (50 μM) for 5 min at 37° C. The selective CYP3A4inhibitor, ketoconazole, is screened alongside the test compounds as apositive control.

For the CYP1A incubations, the reactions are terminated by methanol, andthe formation of the metabolite, resorufin, is monitored by fluorescence(excitation wavelength=535 nm, emission wavelength=595 nm). For theCYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 incubations, the reactionsare terminated by methanol. The samples are then centrifuged, and thesupernatants are combined, for the simultaneous analysis of4-hydroxytolbutamide, 4-hydroxymephenytoin, dextrorphan, and1-hydroxymidazolam by LC-MS/MS. Hydroxybupropion, 6a-hydroxypaclitaxeland 6β-hydroxytestosterone are analysed separately by LC-MS/MS. Formicacid in deionised water (final concentration=0.1%) containing internalstandard is added to the final sample prior to analysis. A decrease inthe formation of the metabolites compared to vehicle control is used tocalculate an IC50 value (test compound concentration which produces 50%inhibition).

Results

CYP450 Calculated Isoform Substrate Metabolite IC₅₀ (μM) 1AEthoxyresorufin Resorufin >25 μM 1A2 Phenacetin Acetaminophen >25 μM 2B6Bupropion Hydroxybupropion 19.2 μM 2C8 Paclitaxel 6α-Hydroxypaclitaxel21.6 μM 2C9 Tolbutamide 4-Hydroxytolbutamide >25 μM 2C19 S-mephenytoin4-Hydroxymephenytoin >25 μM 2D6 Dextromethorphan Dextrorphan 17.7 μM 3A4Midazolam Hydroxymidazolam 2.7 μM 3A4 Testosterone 6 βHydroxytestosterone 10.5 μM.

General Study Design for the Rat Unilateral Ureter Obstruction (UUO)Model of Kidney Fibrosis.

Male Sprague-Dawley rats were fed normal chow, housed under standardconditions, and allowed to acclimate for at least 7 days before surgery.At the inception of study, rats were placed into weight-matched groups,and administered (2 ml/kg p.o. bid) via oral gavage vehicle, one of fourdose levels of compounds (1, 3, 10, or 30 mg/kg). Rats were anesthetizedwith isoflurane anesthesia on a nosecone, and laparotomy was performed.Rats underwent complete obstruction of the right ureter (UUO) using heatsterilized instruments and aseptic surgical technique. Rats wereadministered 50 μl Penicillin G (i.m.) immediately post-operatively.Rats were allowed to recover in a clean, heated cage before beingreturned to normal vivarium conditions. Rats were administered compoundsat the dose described above twice daily (at 12 hour intervals) for thesubsequent 7 days. On day 7 following surgery, rats were anesthetizedwith isoflurane and serum, plasma, and urine collected. Animals werethen euthanized, the kidneys harvested, and renal cortical biopsiescollected for morphological, histological, and biochemical analysis. Alltissues for biochemical analysis are flash-frozen in liquid nitrogen andstored at −80° C., tissues for histological analysis were fixed in 10%neutral buffered formalin

Renal fibrosis was evaluated by measuring the amount of collagen IV inthe kidney by an ELISA method and by examining the accumulation ofalpha-smooth muscle actin positive myofibroblasts in the kidney byimmunohistochemistry. For the former, a small piece of frozen kidneycortex was transferred homengenized in RIPA buffer then centrifuged at14000×g for 10 minutes at at 4° C. The supernatant was collected intopre-chilled tubes and the protein concentration was determined.Equivalent amount of total protein were subjected to a Col IV ELISAassay (Exocell) according to the manufacturers instructions.

Formalin fixed and paraffin embedded kidney tissue was stained with analpha-smooth muscle actin as previously described (Stambe et al., TheRole of p38 Mitogen-Activated Protein Kinase Activation in RenalFibrosis J Am Soc Nephrol 15: 370-379, 2004).

Results:

The compound of formula (I) was found to significantly reduce kidneyCollagen IV induction (FIG. 1) and accumulation of alpha-smooth musclepositive myofibroblasts (FIG. 2) at doses of 3 to 30 mg/kg.

Comparative Data for Compound of Formula (I) and Reference Compounds

The following table provides comparative results for the compound offormula (I) and the reference compounds A and B disclosed in U.S. Patentpublication No. 2001/00095410A1, published Jan. 13, 2011. Applicantsnote that experiments for which results are compared below wereperformed under similar conditions but not necessarily simultaneously.

TABLE Compound of formula (I) Compound A Compound B IC₅₀ (nM) 3 5 6.5EC₅₀ (nM) 2 3.4 18 (9X) PBadj EC₅₀ (nM) 17 71 (4X) 563 (33X) CACO (A/B,B/A) 27/35 3.1/18.5 0.26/4 Efflux ratio (B/A)/ 1.3 6.0 15.4 (A/B) fu 124.8 3.2 Cyp3A4 IC₅₀ 11 1.1 (10X) 4 (2.8X) Testesterone (TST)) (uM)Cyp3A4 IC₅₀/ 647 15 (43X) 7 (92X) PBAdj.EC₅₀ Vss (L/Kg) in rats 0.550.17 (3.2X) 0.54 CL (L/hr/kg) in rats 0.11 0.30 (2.7X) 0.39 (3.6X) % Fin rats 75 11 (6.8X) 50 (1.5X) t½ in rats (hr) 5.07 0.59 (8.6X) 1.3(3.9X) ( ) values in parenthesis represent the number of times thecompound of formula (I) shows an improvement over the indicated compoundfor the indicated parameter.

The following can be deduced from the above comparative data: Thecompound of formula (I) has an EC₅₀ that is comparable to that ofCompound A. The compound of formula (I) has a functional IC₅₀ that iscomparable to IC_(50s) for compounds A and B.

The compound of formula (I) has a protein binding adjusted EC₅₀ that is4 times lower than that of compound A and 33 times lower than that ofcompound B.

The compound of formula (I) is a weaker Cyp3A4 inhibitor compared tocompounds A and B.

The compound of Formula (I) has a CYP3A4 IC₅₀/ PBAdj.EC₅₀ value that is43 times higher than that for compound of formula A, and 92 times higherthan for the compound of formula B.

The compound of formula (I) has a Rat CL value that is 2.7 times lowerthan that for compound of formula A, and 3.6 times lower than that forthe compound of formula B. The compound of formula (I) has a percentbioavailability in rats that is 6.8 times higher than compound A and 1.5times higher than compound B.

The compound of formula (I) has a half life in rats that is 8.6 timeslonger than that of compound A and 3.9 times longer than that ofcompound B.

The above data fairly suggest that the compound of formula (I) hasunexpected and advantageous properties compared to compounds of formulaA and B; and that the compound of formula (I) is likely a bettercandidate for further development for the treatment of chronic kidneydisease, lung and/or kidney fibrosis, and/or cardio-renal diseases.

What is claimed is:
 1. A compound of formula (I)

Namely,5-(4-cyclopropyl-1H-imidazol-1-yl)—N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-2-fluoro-4-methylbenzamide,or a pharmaceutically acceptable salt thereof.
 2. A pharmaceuticalcomposition comprising a therapeutically effective amount of a compoundor pharmaceutically acceptable salt of claim 1 and a pharmaceuticallyacceptable carrier.
 3. A method of treating chronic kidney diseasecomprising administering a therapeutically effective amount of acompound of claim 1, or pharmaceutically acceptable salt thereof, to apatient in need thereof.
 4. A method of treating diabetic kidneydisease, diabetic nephropathy, kidney fibrosis, liver fibrosis, or lungfibrosis comprising administering a therapeutically effective amount ofa compound or pharmaceutically acceptable salt of claim 1, to a patientin need thereof.